<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1F257D5A-AA9A-4460-9953-37368441A1EA"><gtr:id>1F257D5A-AA9A-4460-9953-37368441A1EA</gtr:id><gtr:name>University of Calgary</gtr:name><gtr:address><gtr:line1>2500 University Drive</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5F600791-9929-4BAE-9186-DB9F207BD7C1"><gtr:id>5F600791-9929-4BAE-9186-DB9F207BD7C1</gtr:id><gtr:name>McGill University</gtr:name><gtr:address><gtr:line1>845 Sherbrooke Street W</gtr:line1><gtr:line4>Montreal</gtr:line4><gtr:line5>Quebec, H3A 2T5</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1F257D5A-AA9A-4460-9953-37368441A1EA"><gtr:id>1F257D5A-AA9A-4460-9953-37368441A1EA</gtr:id><gtr:name>University of Calgary</gtr:name><gtr:address><gtr:line1>2500 University Drive</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Canada</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9BBF842B-2C55-4E10-AC83-3950AEE7397B"><gtr:id>9BBF842B-2C55-4E10-AC83-3950AEE7397B</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Sawcer</gtr:surname><gtr:orcidId>0000-0001-7685-0974</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F03019D3-693F-44F5-B1C8-FAD29780F599"><gtr:id>F03019D3-693F-44F5-B1C8-FAD29780F599</gtr:id><gtr:firstName>Maria</gtr:firstName><gtr:surname>Ban</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/147A4A54-6D76-463F-99BD-C21F5AB451A4"><gtr:id>147A4A54-6D76-463F-99BD-C21F5AB451A4</gtr:id><gtr:firstName>Alastair</gtr:firstName><gtr:surname>Compston</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100125"><gtr:id>924EA13B-E102-42AE-AF04-17AA836B1257</gtr:id><gtr:title>Allele specific expression in lymphocyte subsets from patients with multiple sclerosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100125</gtr:grantReference><gtr:abstractText>Multiple sclerosis is the most common cause of neurological disability in young adults. The factors that influence susceptibility and/or govern its highly variable course remain unknown. Over the past three years, several large genome-wide association studies in multiple sclerosis have been completed, providing an unbiased assessment of the factors that influence susceptibility. At present there are 26 known MS genetic markers, and with the recent completion of the largest GWAS in multiple sclerosis of over 10,000 cases, this list will expand considerably. As our knowledge of the genetic factors contributing to disease susceptibility increases, the next priority is to understand the functional consequences of these genetic variants. One such mechanism may be through the regulation of gene expression. We will recruit a large sample of 200 cases and 200 controls and test all common coding variants in genes lying within regions containing established multiple sclerosis susceptibility variants to examine if there is allele specific expression (ASE) in heterozygous samples. By directly examining for the preferential expression of one allele, this provides a measure of the ?real? effect on expression by reducing the effects of environmental and other factors that can influence gene expression. ASE will be analysed in two subpopulations of T cells (CD4+ and CD8+), which are known to be involved in the disease pathology of multiple sclerosis as well as in 64 brain tissue samples. By looking for ASE in both cases and controls we will be able to examine if the spectrum of ASE differs between cases and controls and in examining both T cells and brain tissue we can correlate observed ASE with a particular cell/tissue phenotype.
The susceptibility loci thus far established in multiple sclerosis do not account for all the heritability seen epidemiologically, and it is thought that some of this may be explained by parent-of-origin effects. By recruiting and genotyping both parents of the 200 cases for all the variants studied, we will examine for parent-of-origin effects at loci showing ASE and assess whether these parental effects are restricted to specific cell/tissues.
This systematic analysis of ASE across the regions identified from our genome screening work will provide greater understanding of the effects of associated genetic variants on gene expression. Understanding the cells/tissues in which these effects are present will also help to refine disease mechanisms and promote the development of logical new therapies.</gtr:abstractText><gtr:technicalSummary>Multiple sclerosis is the most common potentially disabling neurological condition that affects young adults in the developed world. The health, social and economic costs of this disease are considerable. Despite substantial improvement in therapeutics, none of the currently available disease-modifying drugs provide long-term benefits. The development of more successful treatments is limited by our poor understanding of pathogenesis and disease mechanisms.
In the last three years Genome-Wide Association Studies (GWAS) in multiple sclerosis have identified numerous novel susceptibility alleles in addition to the long established association with variation in the Human Leukocyte Antigen (HLA) genes from the Major Histocompatibility Complex (MHC). To date association has been established at 26 non-MHC loci and we expect this number to double in the next few months as we complete our latest and most comprehensive GWAS, which is based on almost 10,000 cases. Fine mapping of these regions is underway as part of the IMMUNOCHIP consortium and is expected to identify the functionally relevant variants underlying most of these associations. Immune-relevant genes are heavily over represented in the genomic regions containing these established multiple sclerosis associations and we believe that many of these associated variants are likely to exert their effects on risk by influencing the expression of these nearby genes. 
To investigate this hypothesis we propose to systematically screen the genes mapping close to established multiple sclerosis associations for evidence of cis-acting influences on expression by identifying allele specific expression (ASE) in individuals heterozygous for associated variants. To do this we will complete a large scale investigation of common coding variants from each gene that is in linkage disequilibrium with the established multiple sclerosis variants. We will recruit 200 trio families (an affected individual and both their parents) and 200 unrelated controls. Genomic DNA will be extracted from all 800 individuals and genotyped using Illumina GoldenGate technology. Peripheral blood mononuclear cells will be prepared and CD4+ and CD8+ T lymphocytes isolated from the 200 cases and 200 controls. The ASE of each common coding variant identified will be tested in the cDNA from CD4+ and CD8+ T cells as well as 64 brain tissue samples using Illumina Goldegate. In this way we will be able to simultaneous identify allele specific and parent-of-origin influences on the expression of these genes and correlate this with specific cells.</gtr:technicalSummary><gtr:fund><gtr:end>2013-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>246471</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>McGill University and Genome Quebec Innovation Centre</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>Montreal</gtr:description><gtr:id>B288EF40-7C92-473D-BEAC-47C202232C4C</gtr:id><gtr:impact>No outputs yet</gtr:impact><gtr:outcomeId>eL4X1fuspFk-1</gtr:outcomeId><gtr:partnerContribution>They are performing RNA seq on UK MS samples. I will be included as a co-applicant on applications for funding</gtr:partnerContribution><gtr:piContribution>I have visited and given talks and contributed to meetings. My post doc spent a time there learning techniques. We are working together on RNAseq analysisof MS samples.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>National Institute for Health Research (NIHR) BioResource</gtr:department><gtr:description>Cambridge BioResource</gtr:description><gtr:id>D02A9FE7-4581-4A07-98FA-0E1D8624F1EA</gtr:id><gtr:impact>The main output has been resource building</gtr:impact><gtr:outcomeId>pqAYpMWNWB8-1</gtr:outcomeId><gtr:partnerContribution>Health control subjects for our study are being recruited from the Cambridge BioResource</gtr:partnerContribution><gtr:piContribution>Patients we recruite locally are also joining the Cambridge BioResource.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Calgary</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:description>University of Calgary</gtr:description><gtr:id>F854B80F-D75C-4ABA-BAE7-34238E8648F2</gtr:id><gtr:impact>We have applied for a pilot grant from the endMS network in Canada. This has been awarded</gtr:impact><gtr:outcomeId>545a980998b319.58212293-1</gtr:outcomeId><gtr:partnerContribution>Identification of relevant candidate CSPG genes</gtr:partnerContribution><gtr:piContribution>Genetic dimensions to CSPG research performed in Calgary as present in results from MS GWAS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>72000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant (CD86)</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:fundingRef>955/11</gtr:fundingRef><gtr:id>67DAA1F5-CCA3-4733-B51F-C600D2DC30D4</gtr:id><gtr:outcomeId>qyZqmB53Xp6</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>204303</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant (GALC)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:fundingRef>3</gtr:fundingRef><gtr:id>98F17811-BD5B-4C56-A318-E1EF6F3120A2</gtr:id><gtr:outcomeId>YUqr9bko9So</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>297145</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant (Single Cell)</gtr:description><gtr:end>2019-03-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:fundingRef>43</gtr:fundingRef><gtr:id>BA6A81C0-0E5D-4887-8BCB-2883FF4BB915</gtr:id><gtr:outcomeId>56cdc153f3d7c5.84568095</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>72778</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Network award</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>International Progressive MS Alliance</gtr:fundingOrg><gtr:fundingRef>PA 0115</gtr:fundingRef><gtr:id>07F04043-398C-40AF-AD03-67DF51EBBD56</gtr:id><gtr:outcomeId>545a9ae9c2e300.97502774</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>RNA extracted from patients and controls recruited into the study</gtr:description><gtr:id>D42DE24C-01EB-4924-BF54-2167265DC817</gtr:id><gtr:impact>Sample collection and processing is on-going</gtr:impact><gtr:outcomeId>gHRtn74NLC6</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ASE_RNA_Samples</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B8C5A702-66AA-4487-A341-9E22BEA95359</gtr:id><gtr:title>Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27a61a41bfde3083e5ecad30c6adfbdc"><gtr:id>27a61a41bfde3083e5ecad30c6adfbdc</gtr:id><gtr:otherNames>Lemire M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5675e022c0b80</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ED8B516-3B1E-4EB6-80BE-D27E986FF4A2</gtr:id><gtr:title>Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4396209c07298828c094ab6df480477b"><gtr:id>4396209c07298828c094ab6df480477b</gtr:id><gtr:otherNames>Smets I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a7b72bf8a0551.86196776</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26B2EB90-4E2B-46F4-9B7E-CE14BC9B8E9F</gtr:id><gtr:title>Immunoseq: the identification of functionally relevant variants through targeted capture and sequencing of active regulatory regions in human immune cells.</gtr:title><gtr:parentPublicationTitle>BMC medical genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/012cb2fc2200fa94547f1f1411e43e8d"><gtr:id>012cb2fc2200fa94547f1f1411e43e8d</gtr:id><gtr:otherNames>Morin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1755-8794</gtr:issn><gtr:outcomeId>585d3c8b4a5461.02197438</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100125</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>